[go: up one dir, main page]

WO2009027811A3 - Formes polymorphes d'agonistes de prostaglandine et procédés de fabrication de celles-ci - Google Patents

Formes polymorphes d'agonistes de prostaglandine et procédés de fabrication de celles-ci Download PDF

Info

Publication number
WO2009027811A3
WO2009027811A3 PCT/IB2008/002252 IB2008002252W WO2009027811A3 WO 2009027811 A3 WO2009027811 A3 WO 2009027811A3 IB 2008002252 W IB2008002252 W IB 2008002252W WO 2009027811 A3 WO2009027811 A3 WO 2009027811A3
Authority
WO
WIPO (PCT)
Prior art keywords
sulfonyl
phenoxy
hydrate
pyridine
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/002252
Other languages
English (en)
Other versions
WO2009027811A2 (fr
Inventor
David Burns Damon
Jinyang Hong
Joseph Francis Krzyzaniak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Priority to CA2697950A priority Critical patent/CA2697950A1/fr
Priority to MX2010002300A priority patent/MX2010002300A/es
Priority to US12/675,175 priority patent/US20110046385A1/en
Priority to EP08806952A priority patent/EP2185516A2/fr
Priority to AU2008291814A priority patent/AU2008291814A1/en
Priority to CN200880113737A priority patent/CN101842356A/zh
Publication of WO2009027811A2 publication Critical patent/WO2009027811A2/fr
Publication of WO2009027811A3 publication Critical patent/WO2009027811A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne des formes cristallines polymorphes ou une forme non cristalline ou amorphe du composé sel de sodium d'acide acétique (3-(((4-tert-butyl-benzyl)-(pyridine- 3-sulfonyl)-amino)-méthyl)-phénoxy) ou un hydrate de celui-ci, ainsi que des procédés de préparation de celles-ci, des procédés d'utilisation de celles-ci et des compositions pharmaceutiques les contenant. L'invention concerne également des formes cristallines polymorphes sensiblement pures ou une forme non cristalline ou amorphe du sel de sodium d'acide acétique (3- (((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-méthyl)-phénoxy) ou un hydrate de celui-ci.
PCT/IB2008/002252 2007-08-29 2008-08-25 Formes polymorphes d'agonistes de prostaglandine et procédés de fabrication de celles-ci Ceased WO2009027811A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2697950A CA2697950A1 (fr) 2007-08-29 2008-08-25 Formes polymorphes d'agonistes de prostaglandine et procedes de fabrication de celles-ci
MX2010002300A MX2010002300A (es) 2007-08-29 2008-08-25 Polimorfos de sal sodica del acido (3-(((4-terc-butil-bencil)-(pir idin-3-sulfonil)-amino)-metil)-fenoxi)-acetico o un hidrato de los mismos y procedimientos para fabricar los mismos.
US12/675,175 US20110046385A1 (en) 2007-08-29 2008-08-25 Polymorphs Of Prostaglandin Agonists And Methods For Making The Same
EP08806952A EP2185516A2 (fr) 2007-08-29 2008-08-25 Formes polymorphes d'agonistes de prostaglandine et procédés de fabrication de celles-ci
AU2008291814A AU2008291814A1 (en) 2007-08-29 2008-08-25 Polymorphs of 3- ( ( (4-tert-butyl-benzyl) - (pyridine-3-sulfonyl) -amino) -methyl) -phenoxy) -acetic acid sodium salt or a hydrate thereof and methods for making the same
CN200880113737A CN101842356A (zh) 2007-08-29 2008-08-25 (3-(((4-叔丁基苄基)-(吡啶-3-磺酰基)-氨基)-甲基)-苯氧基)-乙酸钠盐或其水合物的多晶型体及其制备方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US96877107P 2007-08-29 2007-08-29
US60/968,771 2007-08-29
US8355908P 2008-07-25 2008-07-25
US61/083,559 2008-07-25

Publications (2)

Publication Number Publication Date
WO2009027811A2 WO2009027811A2 (fr) 2009-03-05
WO2009027811A3 true WO2009027811A3 (fr) 2009-06-11

Family

ID=40042625

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/002252 Ceased WO2009027811A2 (fr) 2007-08-29 2008-08-25 Formes polymorphes d'agonistes de prostaglandine et procédés de fabrication de celles-ci

Country Status (9)

Country Link
EP (1) EP2185516A2 (fr)
JP (1) JP2009137934A (fr)
KR (1) KR20100050559A (fr)
CN (1) CN101842356A (fr)
AR (1) AR068349A1 (fr)
AU (1) AU2008291814A1 (fr)
CA (1) CA2697950A1 (fr)
MX (1) MX2010002300A (fr)
WO (1) WO2009027811A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE031738T2 (en) * 2009-02-27 2017-07-28 Janssen Pharmaceuticals Inc Amorphous salt of a macrocyclic inhibitor of hcv
EP3759070A4 (fr) * 2018-02-28 2021-12-08 Bridge Biotherapeutics, Inc. Sels hydrosolubles de peptides lipidés et leurs procédés de préparation et d'utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999019300A1 (fr) * 1997-10-10 1999-04-22 Pfizer Inc. Agonistes de la prostaglandine et leur utilisation pour le traitement des problemes osseux

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999019300A1 (fr) * 1997-10-10 1999-04-22 Pfizer Inc. Agonistes de la prostaglandine et leur utilisation pour le traitement des problemes osseux

Also Published As

Publication number Publication date
EP2185516A2 (fr) 2010-05-19
CA2697950A1 (fr) 2009-03-05
MX2010002300A (es) 2010-03-18
KR20100050559A (ko) 2010-05-13
JP2009137934A (ja) 2009-06-25
CN101842356A (zh) 2010-09-22
AR068349A1 (es) 2009-11-11
WO2009027811A2 (fr) 2009-03-05
AU2008291814A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
WO2010001257A3 (fr) Nouvelles formes à l’état solide de laquinimod et son sel de sodium
WO2009083940A3 (fr) Procédés pour l'élaboration de sels d'acide 2,5-dihydroxybenzènesulfonique
WO2008146308A3 (fr) Procédé de préparation de chlorhydrate d'ivabradine et polymorphe correspondant
WO2007047863A3 (fr) Cristaux de sodium de laquinimod, et procede de fabrication de ceux-ci
WO2009066326A3 (fr) Procédé amélioré pour la préparation de prasugrel et de ses sels pharmaceutiquement acceptables
WO2011141933A3 (fr) Procédé pour la préparation d'acide 2-[3-cyano-4-(2-méthylpropoxy)phényl]-4-méthylthiazole-5-carboxylique et ses sels acceptables sur le plan pharmaceutique
WO2008155615A3 (fr) Procédé perfectionné pour la préparation d'un antibiotique de la famille des céphalosporines
WO2010139981A3 (fr) Procédés d'élaboration de formes cristallines
WO2011024192A3 (fr) Nouveaux polymorphes du raltegravir
WO2010076810A3 (fr) Procédé d'élaboration de géfitinibe
WO2010070677A3 (fr) Procédé de préparation de prasugrel et de ses sels pharmaceutiquement acceptables
WO2007088545A3 (fr) Nouveau procédé pour la préparation de l'acide 1-[(mercaptométhyl)cyclopropane]acétique, un intermédiaire utile dans la préparation de montelukaste et des ses sels
WO2008117305A3 (fr) Nouveau procédé pour préparer de la prégabaline et ses sels d'addition avec les acides
WO2010079045A3 (fr) Nouveaux sels
WO2009037538A3 (fr) Procédé de préparation de lamivudine de forme i
WO2008015703A3 (fr) Procédé pour la préparation de montelukast et de ses sels
WO2007096875A3 (fr) Nouveaux polymorphes de sels d'ammonium de montelukast et leurs procedes de preparation
WO2008049922A3 (fr) Nouveau procédé de préparation du montélukast
WO2008009970A3 (fr) Procédé
WO2008081476A3 (fr) Procédé d'élaboration de chlorhydrate de duloxétine
WO2009060297A3 (fr) Procédé perfectionné pour la préparation de la palipéridone et de ses intermédiaires
WO2011135586A3 (fr) Procédé de préparation de dérivés chiraux de bêta-amino carboxamide
WO2009027811A3 (fr) Formes polymorphes d'agonistes de prostaglandine et procédés de fabrication de celles-ci
WO2009122429A3 (fr) Oxybutynine cristalline et son procédé de préparation
WO2009021943A3 (fr) Nouveau procédé de préparation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880113737.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08806952

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 203795

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008291814

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1143/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2697950

Country of ref document: CA

Ref document number: MX/A/2010/002300

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008291814

Country of ref document: AU

Date of ref document: 20080825

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008806952

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107006782

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12675175

Country of ref document: US